-
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-26 André Pontes-Silva
Abstract not available
-
Reply to Anju Murayama’s Letter to the Editor re: David-Dan Nguyen, Liam Murad, Anne Xuan-Lan Nguyen, et al. Industry Payments to American Editorial Board Members of Major Urology Journals. Eur Urol. Eur Urol. 2023;84:442–43 Eur. Urol. (IF 23.4) Pub Date : 2023-09-26 David-Dan Nguyen, Anna-Lisa V. Nguyen, Liam Murad, Muhieddine Labban, Quoc-Dien Trinh, Christopher J.D. Wallis, Naeem Bhojani
Abstract not available
-
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass) Eur. Urol. (IF 23.4) Pub Date : 2023-09-26 Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, Manfred Wirth, Peter Staib, Martin Schostak, Philip Dargatz, Lothar Müller, Michael Metz, Lothar Bergmann, Thomas Steiner, Martin Welslau, Anja Lorch, Reza Rafiyan, Eva Hellmis, Cristopher Darr, Philipp Schütt, Johannes Meiler, Thomas Kretz, Wolfgang Loidl, Carsten Grüllich
Background The role of immune checkpoint inhibitor (ICI) maintenance therapy in metastatic renal cell carcinoma (mRCC) is undefined. Objective To determine whether switch maintenance therapy with nivolumab improves clinical outcomes in patients with mRCC with tyrosine kinase inhibitor (TKI) sensitivity. Design, setting, and participants This open-label phase 2 trial randomized patients with a partial
-
Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.039 Eur. Urol. (IF 23.4) Pub Date : 2023-09-23 Adrian Pilatz, Steven MacLennan, Roderick C.N. van den Bergh, Rajan Veeratterapillay, Muhammad Imran Omar, Yuhong Yuan, Phillip Cornford, Gernot Bonkat
Abstract not available
-
Erratum to “Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion” [Eur. Urol. 75(5) (2019) 752–763] Eur. Urol. (IF 23.4) Pub Date : 2023-09-23 Qiang Fu, Le Xu, Yiwei Wang, Qi Jiang, Zheng Liu, Junyu Zhang, Quan Zhou, Han Zeng, Shanyou Tong, Tao Wang, Yangyang Qi, Baoying Hu, Hangcheng Fu, Huyang Xie, Lin Zhou, Yuan Chang, Yu Zhu, Bo Dai, Weijuan Zhang, Jiejie Xu
Abstract not available
-
Neuropsychiatric Developmental Disorders in Children Are Associated With an Impaired Response to Treatment in Bladder Bowel Dysfunction: A Prospective Multi-Institutional European Observational Study. J. Urol. (IF 6.6) Pub Date : 2023-09-25 F O'Kelly, L A t'Hoen, S Silay, R J M Lammers, S Sforza, E Bindi, N Baydilli, M I Donmez, I Paraboschi, A Atwa, A F Spinoit, B Banuelos Marco
Bladder and bowel dysfunction is a common but underdiagnosed pediatric entity which may represent up to 47% of pediatric urology consults. The objectives of this observational study were to determine functional 1-year outcomes following standard treatment of bladder and bowel dysfunction in both control and neuropsychiatric developmental disorder groups using validated questionnaires, and to perform
-
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Matthias May, Ingmar Wolff, Sabine D. Brookman-May
Abstract not available
-
Reply to André Pontes-Silva’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Gabriela Ilie, Robert David Harold Rutledge
Abstract not available
-
Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Gabriela Ilie, Robert David Harold Rutledge
Abstract not available
-
Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization? Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Sriram Deivasigamani, Srinath Kotamarti, Rajan T. Gupta, Thomas J. Polascik
Abstract not available
-
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Daniela-Elena Oprea-Lager, Steven MacLennan, Anders Bjartell, Alberto Briganti, Irene A. Burger, Igle de Jong, Maria De Santis, Uta Eberlein, Louise Emmett, Karim Fizazi, Silke Gillessen, Ken Herrmann, Sandra Heskamp, Andrei Iagaru, Barbara Alicja Jereczek-Fossa, Jolanta Kunikowska, Marnix Lam, Cristina Nanni, Joe M. O'Sullivan, Valeria Panebianco, Stefano Fanti
Background In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA radioligand therapy, integration of advanced imaging in nomogram-based decision-making, dosimetry, and development of new theranostic applications. Objective We aimed to critically review developments in molecular hybrid imaging and systemic
-
Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Laurence Klotz
Abstract not available
-
Improved phenotypic classification of male infertility to promote discovery of genetic causes Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-09-18 Margot J. Wyrwoll, Godfried W. van der Heijden, Csilla Krausz, Kenneth I. Aston, Sabine Kliesch, Robert McLachlan, Liliana Ramos, Donald F. Conrad, Moira K. O’Bryan, Joris A. Veltman, Frank Tüttelmann
-
Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-09-16 Trine Strandgaard, Iver Nordentoft, Karin Birkenkamp-Demtröder, Liina Salminen, Frederik Prip, Julie Rasmussen, Tine Ginnerup Andreasen, Sia Viborg Lindskrog, Emil Christensen, Philippe Lamy, Michael Knudsen, Torben Steiniche, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
Background Field cancerization is characterized by areas of normal tissue affected by mutated clones. Bladder field cancerization may explain the development and recurrence of bladder cancer and may be associated with treatment outcomes. Objective To investigate the predictive and prognostic roles of field cancerization in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) treated with
-
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U Eur. Urol. (IF 23.4) Pub Date : 2023-09-12 Hendrik Van Poppel, Monique J. Roobol, Arunah Chandran
Abstract not available
-
-
-
-
-
Continence criteria of 193,618 patients after open, laparoscopic, and robotic radical prostatectomy BJU Int. (IF 4.5) Pub Date : 2023-09-15 Tomás B. C. Moretti, Luís A. Magna, Leonardo O. Reis
to apply a new evidence-gathering methodology, called reverse systematic review (RSR), to analyze the influence of different continence classification criteria on urinary continence rates among open (RRP), laparoscopic (LRP) and robotic (RARP) radical prostatectomy.
-
Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa BJU Int. (IF 4.5) Pub Date : 2023-09-13 Mohamed Jalloh, Ayun Cassell, Lamine Niang, Timothy Rebbeck
Prostate cancer is a major health concern in Sub-Saharan Africa (SSA), with high incidence and mortality rates. However, the widely used prostate-specific antigen (PSA) screening is not readily available or affordable in SSA. Alternative screening strategies, such as risk stratification approaches and cost-effective PSA tests, are being explored to target high-risk individuals and improve access to
-
Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer BJU Int. (IF 4.5) Pub Date : 2023-09-13 F. Lehner, A. Crippa, S. Sigg, D. Eberli, A. Mortezavi
To evaluate the performance of risk calculators (RCs) predicting lymph node invasion (LNI) and extraprostatic extension (EPE) in men undergoing transperineal MRI/TRUS-fusion template saturation biopsy (TTSB) and conventional systematic transrectal TRUS-guided biopsy (SB).
-
Barriers and enablers of active surveillance for prostate cancer – a qualitive study of clinicians BJU Int. (IF 4.5) Pub Date : 2023-09-11 Trent A Pattenden, Isaac A Thangasamy, Wee Loon Ong, Dhanika Samaranayke, Andrew Morton, Declan G Murphy, Susan Evans, Jeremy Millar, Venu Chalasani, Prem Rashid, Matthew Winter, Ian Vela, David Pryor, Stephen Mark, Stacy Loeb, Nathan Lawrentschuk, Elizabeth Pritchard
To identify and explore barriers to, and enablers of active surveillance (AS) in men with low-risk prostate cancer (LRPC), as perceived by prostate cancer clinicians.
-
Prevalence of urolithiasis in China: A systematic review and meta-analysis BJU Int. (IF 4.5) Pub Date : 2023-09-11 Songsong Tan, Dongbo Yuan, Hao Su, Weihong Chen, Siqi Zhu, Bo Yan, Fa Sun, Kehua Jiang, Jianguo Zhu
China has a large population and complex geographical environment, which is lead to a large number of urolithiasis patients. However, there is a dearth of comprehensive investigations of urolithiasis prevalence. Consequently, This study aimed to estimate the pooled prevalence , as well as the spatial and temporal distribution, urolithiasis among subjects in China.
-
Re: David-Dan Nguyen, Liam Murad, Anne Xuan-Lan Nguyen, et al. Industry Payments to American Editorial Board Members of Major Urology Journals. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.04.017 Eur. Urol. (IF 23.4) Pub Date : 2023-09-14 Anju Murayama
Abstract not available
-
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance Eur. Urol. (IF 23.4) Pub Date : 2023-09-14 Srikala S. Sridhar, Thomas Powles, Miguel Á. Climent Durán, Se Hoon Park, Francesco Massari, Antoine Thiery-Vuillemin, Begoña P. Valderrama, Anders Ullén, Norihiko Tsuchiya, Jeanny B. Aragon-Ching, Shilpa Gupta, Daniel P. Petrylak, Joaquim Bellmunt, Jing Wang, Robert J. Laliberte, Alessandra di Pietro, Nuno Costa, Petros Grivas, Cora N. Sternberg, Yohann Loriot
Background In the JAVELIN Bladder 100 phase 3 trial, avelumab first-line maintenance + best supportive care (BSC) prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (advanced UC) without progression after first-line platinum-based chemotherapy. Objective To report post hoc analyses of subgroups defined by the duration
-
Reply to Laura E. Davis, Adam Calaway, and Laura Bukavina’s Letter to the Editor re: Nima Nassiri, Giovanni Cacciamani, Inderbir S. Gill. Robotic Bladder Auto-transplantation in a Heart-beating Brain-dead Human Research Donor. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.06.004 Eur. Urol. (IF 23.4) Pub Date : 2023-09-14 Nima Nassiri, Giovanni E. Cacciamani, Inderbir S. Gill
Abstract not available
-
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023 Eur. Urol. (IF 23.4) Pub Date : 2023-09-10 Kentaro Inamura
Abstract not available
-
Feasibility and potential of an MRI-based prostate cancer screening Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-09-11 Maria Chiara Masone
Prostate cancer screening using prostate-specific antigen (PSA) followed by biopsy has been shown to reduce mortality but results in overdiagnosis and overtreatment in a substantial percentage of patients.
-
Accessing information in the AI age Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-09-11 Louise Stone
Online sources are increasingly being used by patients to obtain medical information. The newest of these resources, artificial intelligence (AI) chatbots, are becoming ever more popular tools with the public and could be accurate sources of information. Another accessible and approachable format is the podcast. However, the veracity and utility of these sources of information need investigation.
-
Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Martin C. Michel
Abstract not available
-
Re: Deep Learning Imaging Features Derived from Kidney Ultrasounds Predict Chronic Kidney Disease Progression in Children with Posterior Urethral Valves Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Lisette A. 't Hoen
Abstract not available
-
Re: Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Christopher Netsch
Abstract not available
-
Re: Stavros Gravas, Mauro Gacci, Christian Gratzke, et al. Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol. 2023;84:207–22 Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Francesco Montorsi, Paolo Capogrosso, Federico Dehò, Andrea Salonia
Abstract not available
-
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Joana B. Neves, Hannah Warren, Joseph Santiapillai, Nicola Rode, David Cullen, Menelaos Pavlou, Miles Walkden, Prasad Patki, Ravi Barod, Faiz Mumtaz, Michael Aitchison, Steven Bandula, Elena Pizzo, Veronica Ranieri, Norman Williams, William Wildgoose, Kurinchi Gurusamy, Mark Emberton, Axel Bex, Maxine G.B. Tran
There is a paucity of high-level evidence on small renal mass (SRM) management, as previous classical randomised controlled trials (RCTs) failed to meet accrual targets. Our objective was to assess the feasibility of recruitment to a cohort-embedded RCT comparing cryoablation (CRA) to robotic partial nephrectomy (RPN). A total of 200 participants were recruited to the cohort, of whom 50 were enrolled
-
Re: Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Mikkel Fode, Christian Fuglesang S. Jensen, Jens Sønksen
Abstract not available
-
Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547–58 Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Bernardo Rocco, Maria Chiara Sighinolfi
Abstract not available
-
Re: Nima Nassiri, Giovanni Cacciamani, Inderbir S. Gill. Robotic Bladder Auto-transplantation in a Heart-beating Brain-dead Human Research Donor. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.06.004 Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Laura E. Davis, Adam Calaway, Laura Bukavina
Abstract not available
-
Proteomic-based analysis of testicular interstitial fluid Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-09-08 Maria Chiara Masone
Proteomic-based approaches are increasingly being used to assess alterations in the proteomic profile of seminal plasma in men with infertility with the aim to characterize the molecular pathways responsible for altered spermatogenesis and identify potential biomarkers. However, testes are responsible for a limited portion of the seminal plasma proteome, and limited information is available about dysregulations
-
A fully transperineal approach for prostate biospy Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-09-08 Maria Chiara Masone
Transperineal (TP) biopsy for prostate cancer shows similar cancer detection rates to those obtained with transrectal (TR) biopsy but has the advantage of reducing infections. However, TP biopsy is performed using a transrectal ultrasound (TRUS) probe to guide the needle, which might cause discomfort and is still associated with the disadvantages and complications of a TR procedure.
-
Randomized trial of holmium laser vs. thulium laser vs. bipolar enucleation of large size prostate BJU Int. (IF 4.5) Pub Date : 2023-09-05 Ahmed M Shoma, Fady K. Ghobrial, Nasr El-Tabey, Ahmed S. El-Hefnawy, Hamdy A. El-Kappany
To compare the outcome and morbidity of B-TUEP and ThuLEP to HoLEP in treatment of large symptomatic benign prostatic obstruction (BPO) through non inferiority randomized controlled trial (NCT03916536).
-
Real-time Estimation of Nephron Activity with a Linear Measurement System (RENAL-MS) Predicts Postoperative eGFR BJU Int. (IF 4.5) Pub Date : 2023-09-04 Jared P. Schober, Kevin B. Ginsburg, Alexander Kutikov, Eric Y Cho, Matt Loecher, David Strauss, Alberto Andres Castro Bigalli, Elizabeth Handorf, Mengying Deng M. Math, Jordan Anaokar, David YT. Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Andres F. Correa, Robert G. Uzzo, Marshall Strother
Preoperative nuclear medicine renal scintigraphy (NMRS) is often used to predict estimated glomerular filtration (eGFR) after nephrectomy by estimating preoperative split renal function. We sought to determine whether a simple point-of-care measurement system estimating renal parenchymal volume using tools ubiquitously available could be used to replace NMRS in current clinical practice.
-
Robotic Bladder Autotransplantation: Preclinical Studies in Preparation for First-in-human Bladder Transplant. J. Urol. (IF 6.6) Pub Date : 2023-09-08 Nima Nassiri, Giovanni Cacciamani, Inderbir S Gill
Human urinary bladder transplantation has never been performed. From a technical standpoint, challenges include the complex deep pelvic vascular anatomy, limited intraoperative visualization, and high procedural complexity. In preparation for a first-in-human clinical trial, we report preclinical studies to develop the technique of robotic retrieval and autotransplantation of vascularized composite
-
The Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death. J. Urol. (IF 6.6) Pub Date : 2023-09-08 Blayne Welk, J Andrew McClure
Male lower urinary tract symptoms have been correlated with an increased risk of death; however, it is unclear if treatment will reduce this risk. Our objective was to determine whether a reduction in lower urinary tract symptoms is associated with a reduced risk of mortality.
-
Methodological Rigour in Preclinical Urology: a 14-year systematic review reporting research quality BJU Int. (IF 4.5) Pub Date : 2023-09-04 Seung Hyun Park, Se Bee Lee, Seoyeon Park, Eun Young Kim, Damiano Pizzol, Mike Trott, Yvonne Barnett, Ai Koyanagi, Louis Jacob, Pinar Soysal, Nicola Veronese, Simona Ippoliti, Ramy Abou Ghayda, Nannan Thirumavalavan, Adonis Hijaz, David Sheyn, Rachel Pope, Britt Conroy, Irina Jaeger, Gupta Shubham, Amihay Nevo, Petre Cristian Ilie, Seung Won Lee, Dong Keon Yon, Hyun Ho Han, Sung Hwi Hong, Jae Il Shin
The demand for methodological rigour in preclinical studies is increasing since the research reproducibility and transparency in the medico-scientific field are being questioned. As a result, we investigated the prevalence and the trends of essential study design elements in preclinical urological studies, as well as key factors which may improve methodological rigour.
-
Reducing the risks of nuclear war – the role of health professionals BJU Int. (IF 4.5) Pub Date : 2023-09-05 Kamran Abbasi, Parveen Ali, Virginia Barbour, Kirsten Bibbins-Domingo, Marcel GM Olde Rikkert, Andy Haines, Ira Helfand, Richard Horton, Bob Mash, Arun Mitra, Carlos Monteiro, Elena N. Naumova, Eric J. Rubin, Tilman Ruff, Peush Sahni, James Tumwine, Paul Yonga, Chris Zielinski
In January, 2023, the Science and Security Board of the Bulletin of the Atomic Scientists moved the hands of the Doomsday Clock forward to 90 s before midnight, reflecting the growing risk of nuclear war.1 In August, 2022, the UN Secretary-General António Guterres warned that the world is now in “a time of nuclear danger not seen since the height of the Cold War.2 The danger has been underlined by
-
Risk of Local Recurrence in Men With Penile Intraepithelial Neoplasia in the Surgical Margin After Penile-sparing Surgery. J. Urol. (IF 6.6) Pub Date : 2023-09-07 Esther W C Lee, Luca Antonelli, Allaudin Issa, James Churchill, Ashwin Sachdeva, Pedro Oliveira, Maurice Lau, Vijay Sangar, Arie Parnham, Christian D Fankhauser
Up to 90% of men with a positive surgical margin show remaining cancer in subsequent reresections. The risk of local recurrence in men with no penile cancer but the precancerous lesion penile intraepithelial neoplasia at the surgical margin is less well studied and was the aim of this analysis.
-
The Role of 99mTc‐Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta‐analysis Eur. Urol. (IF 23.4) Pub Date : 2023-09-05 Giuseppe Basile, Giuseppe Fallara, Paolo Verri, Alessandro Uleri, Arturo Chiti, Luigi Gianolli, Gino Pepe, Alessandro Tedde, Ferran Algaba, Angelo Territo, Francesco Sanguedolce, Alessandro Larcher, Andrea Gallioli, Joan Palou, Francesco Montorsi, Umberto Capitanio, Alberto Breda
Context The diagnostic accuracy of current imaging techniques in differentiating benign from malignant neoplasms in the case of indeterminate renal masses is still suboptimal. Objective To evaluate the diagnostic accuracy of 99mTc-sestamibi (SestaMIBI) single-photon emission tomography computed tomography (SPECT)/CT in characterizing indeterminate renal masses by differentiating renal oncocytoma and
-
Metaverse Surgical Planning with Three-dimensional Virtual Models for Minimally Invasive Partial Nephrectomy Eur. Urol. (IF 23.4) Pub Date : 2023-09-04 Enrico Checcucci, Daniele Amparore, Gabriele Volpi, Sabrina De Cillis, Federico Piramide, Paolo Verri, Alberto Piana, Michele Sica, Cecilia Gatti, Paolo Alessio, Alberto Quarà, Mariano Burgio, Marco Colombo, Giovanni Busacca, Alex Mottrie, Edward Cherullo, Alberto Breda, Alessandro Antonelli, Renaud Bollens, Andrea Minervini, Francesco Porpiglia
The recent integration of new virtual visualization modalities with artificial intelligence and high-speed internet connection has opened the door to the advent of the metaverse in medicine. In this totally virtual environment, three-dimensional virtual models (3DVMs) of the patient’s anatomy can be visualized and discussed via digital avatars. Here we present for the first time a metaverse preoperative
-
A clinical guide to rare male sexual disorders Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-09-05 Murat Gül, Mikkel Fode, Ahmet Urkmez, Paolo Capogrosso, Marco Falcone, Selcuk Sarikaya, Ioannis Sokolakis, Afonso Morgado, Andrey Morozov, Maarten Albersen, Giorgio Ivan Russo, Ege Can Serefoglu
-
Membranous urethral length and urinary incontinence following robot-assisted radical prostatectomy: a systematic review and meta-analysis BJU Int. (IF 4.5) Pub Date : 2023-09-04 Benjamin M. Mac Curtain, Diarmuid D. Sugrue, Wanyang Qian, Michael O'Callaghan, Niall F. Davis
To provide an update on the association between preoperative membranous urethral length (MUL) and postoperative urinary incontinence (UI) in men who undergo robot-assisted radical prostatectomy (RARP)/robot-assisted laparoscopic prostatectomy (RALP).
-
Retrospective first-in-human use of the LithoVue™ Elite ureteroscope to measure intrarenal pressure BJU Int. (IF 4.5) Pub Date : 2023-09-04 Naeem Bhojani, Kyo Chul Koo, Kahina Bensaadi, Abdulghafour Halawani, Victor KF. Wong, Ben H. Chew
To report on our first-in-human experience using the LithoVue Elite™ ureteroscope (Boston Scientific Corp., Marlborough, MA, USA) to measure intrarenal pressure (IRP) during flexible ureteroscopy.
-
Reply to Thomas Seisen, Morgan Rouprêt, and Pierre Blanchard’s Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669–81 Eur. Urol. (IF 23.4) Pub Date : 2023-09-01 Alexandre R. Zlotta, Katherine Lajkosz, Jason A. Efstathiou
Abstract not available
-
Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95–108 Eur. Urol. (IF 23.4) Pub Date : 2023-08-31 Yao-Ning Feng, Guang-Yu Xie, Li Xiao
Abstract not available
-
Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] Eur. Urol. (IF 23.4) Pub Date : 2023-09-02 Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen-Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini
Abstract not available
-
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol 2023;84:109–16 Eur. Urol. (IF 23.4) Pub Date : 2023-09-01 Jonas Saal, Viktor Grünwald, Niklas Klümper
Abstract not available
-
Reply to Bernardo Rocco and Maria Chiara Sighinolfi’s Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58 Eur. Urol. (IF 23.4) Pub Date : 2023-09-01 Freddie C. Hamdy, Jenny L. Donovan
Abstract not available
-
Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669–81 Eur. Urol. (IF 23.4) Pub Date : 2023-08-31 Thomas Seisen, Morgan Rouprêt, Pierre Blanchard
Abstract not available
-
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression Eur. Urol. (IF 23.4) Pub Date : 2023-08-31 Alexandros Papachristodoulou, Isabel Heidegger, Renu K. Virk, Matteo Di Bernardo, Jaime Y. Kim, Caroline Laplaca, Florencia Picech, Georg Schäfer, Guarionex Joel De Castro, Hanina Hibshoosh, Massimo Loda, Helmut Klocker, Mark A. Rubin, Tian Zheng, Mitchell C. Benson, James M. McKiernan, Aditya Dutta, Cory Abate-Shen
Background The antidiabetic drug metformin has known anticancer effects related to its antioxidant activity; however, its clinical benefit for prostate cancer (PCa) has thus far been inconclusive. Here, we investigate whether the efficacy of metformin in PCa is related to the expression status of NKX3.1, a prostate-specific homeobox gene that functions in mitochondria to protect the prostate from aberrant
-
In vivo ureteroscopic intrarenal pressures and clinical outcomes: a multi-institutional analysis of 120 consecutive patients BJU Int. (IF 4.5) Pub Date : 2023-09-01 Stefanie M. Croghan, Eoghan M. Cunnane, Sorcha O'Meara, Muheilan Muheilan, Connor V. Cunnane, Kenneth Patterson, Andreas Skolarikos, Bhaskar Somani, Gregory S. Jack, James C. Forde, Fergal J. O'Brien, Michael T. Walsh, Rustom P. Manecksha, Barry B. McGuire, Niall F. Davis
To evaluate the pressure range generated in the human renal collecting system during ureteroscopy (URS), in a large patient sample, and to investigate a relationship between intrarenal pressure (IRP) and outcome.